FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:20-28 January 6, 2005 Number 1 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Ehrenstein, M. R. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown.

Methods We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes.

Results Patients in whom statin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter (1.8 mmol per liter) had lower event rates than those with higher levels (2.7 vs. 4.0 events per 100 person-years, P=0.008). However, a virtually identical difference was observed between those who had CRP levels of less than 2 mg per liter after statin therapy and those who had higher levels (2.8 vs. 3.9 events per 100 person-years, P=0.006), an effect present at all levels of LDL cholesterol achieved. For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P<0.001). Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Patients who had LDL cholesterol levels of less than 70 mg per deciliter and CRP levels of less than 1 mg per liter after statin therapy had the lowest rate of recurrent events (1.9 per 100 person-years).

Conclusions Patients who have low CRP levels after statin therapy have better clinical outcomes than those with higher CRP levels, regardless of the resultant level of LDL cholesterol. Strategies to lower cardiovascular risk with statins should include monitoring CRP as well as cholesterol.

Source Information

From the Center for Cardiovascular Disease Prevention (P.M.R., N.R., L.M.R.), the Donald W. Reynolds Center for Cardiovascular Research (P.M.R., D.M., N.R.), and the Thrombolysis in Myocardial Infarction Study Group (C.P.C., D.M., C.H.M., M.A.P., E.B.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.

Address reprint requests to Dr. Ridker at the Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, 900 Commonwealth Ave. East, Boston, MA 02215, or at pridker{at}partners.org.

Full Text of this Article

Related Letters:

C-Reactive Protein Levels and Outcomes after Statin Therapy
Cohen B., Singh D., Greenland P., Lloyd-Jones D. M., Moss A. J., Jaber B. L., Madias N. E., Ridker P. M, Cannon C. P., Braunwald E.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:1603-1605, Apr 14, 2005. Correspondence

This article has been cited by other articles:

• POLDERMANS, D. (2009). Statins and noncardiac surgery: Current evidence and practical considerations. Cleveland Clinic Journal of Medicine 76: S79-S83 [Abstract] [Full Text]  
• Eldor, R., Raz, I. (2009). American Diabetes Association Indications for Statins in Diabetes: Is there evidence?. Diabetes Care 32: S384-S391 [Full Text]  
• Klingenberg, R., Hansson, G. K. (2009). Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 0: ehp477v1-ehp477 [Abstract] [Full Text]  
• U.S. Preventive Services Task Force, (2009). Using Nontraditional Risk Factors in Coronary Heart Disease Risk Assessment: U.S. Preventive Services Task Force Recommendation Statement. ANN INTERN MED 151: 474-482 [Abstract] [Full Text]  
• Buckley, D. I., Fu, R., Freeman, M., Rogers, K., Helfand, M. (2009). C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force. ANN INTERN MED 151: 483-495 [Abstract] [Full Text]  
• Helmers, A. J., Gowda, D. C., Kain, K. C., Liles, W. C. (2009). Statins Fail to Improve Outcome in Experimental Cerebral Malaria and Potentiate Toll-Like Receptor-Mediated Cytokine Production by Murine Macrophages. Am J Trop Med Hyg 81: 631-637 [Abstract] [Full Text]  
• Kumar, A., Cannon, C. P. (2009). Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clin Proc. 84: 917-938 [Abstract] [Full Text]  
• Sixt, S., Beer, S., Bluher, M., Korff, N., Peschel, T., Sonnabend, M., Teupser, D., Thiery, J., Adams, V., Schuler, G., Niebauer, J. (2009). Long- but not short-term multifactorial intervention with focus on exercise training improves coronary endothelial dysfunction in diabetes mellitus type 2 and coronary artery disease. Eur Heart J 0: ehp398v1-ehp398 [Abstract] [Full Text]  
• Conen, D., Rexrode, K. M., Creager, M. A., Ridker, P. M, Pradhan, A. D. (2009). Metabolic Syndrome, Inflammation, and Risk of Symptomatic Peripheral Artery Disease in Women: A Prospective Study. Circulation 120: 1041-1047 [Abstract] [Full Text]  
• Schouten, O., Boersma, E., Hoeks, S. E., Benner, R., van Urk, H., van Sambeek, M. R.H.M., Verhagen, H. J.M., Khan, N. A., Dunkelgrun, M., Bax, J. J., Poldermans, D., the Dutch Echocardiographic Cardiac Risk Evaluatio, (2009). Fluvastatin and Perioperative Events in Patients Undergoing Vascular Surgery. NEJM 361: 980-989 [Abstract] [Full Text]  
• Swedberg, K. (2009). Fallacies in clinical cardiovascular trials. Heart 95: 1464-1468 [Full Text]  
• Devaraj, S., Yun, J.-M., Adamson, G., Galvez, J., Jialal, I. (2009). C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc Res 0: cvp249v2-cvp249 [Abstract] [Full Text]  
• deFilippi, C. R., Seliger, S. L. (2009). Biomarkers for prognostication after acute coronary syndromes: new times and statistics.. J Am Coll Cardiol 54: 365-367 [Full Text]  
• Bankier, B., Barajas, J., Martinez-Rumayor, A., Januzzi, J. L. (2009). Association Between Anxiety and C-Reactive Protein Levels in Stable Coronary Heart Disease Patients. Psychosomatics 50: 347-353 [Abstract] [Full Text]  
• Wheeler, D. C. (2009). The Jupiter trial--new territory for statins?. Nephrol Dial Transplant 24: 2036-2037 [Full Text]  
• Nasu, K., Tsuchikane, E., Katoh, O., Tanaka, N., Kimura, M., Ehara, M., Kinoshita, Y., Matsubara, T., Matsuo, H., Asakura, K., Asakura, Y., Terashima, M., Takayama, T., Honye, J., Hirayama, A., Saito, S., Suzuki, T. (2009). Effect of Fluvastatin on Progression of Coronary Atherosclerotic Plaque Evaluated by Virtual Histology Intravascular Ultrasound. J Am Coll Cardiol Intv 2: 689-696 [Abstract] [Full Text]  
• Ridker, P. M (2009). The JUPITER Trial: Results, Controversies, and Implications for Prevention. Circ Cardiovasc Qual Outcomes 2: 279-285 [Full Text]  
• Libby, P. (2009). Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J. Lipid Res. 50: S352-S357 [Abstract] [Full Text]  
• Gibbons, R. J., Fugh-Berman, A., Chan, P. S., Nallamothu, B. K., Hayward, R. A., Jenny-Avital, E. R., Mak, K.-H., Chan, E. S.-Y., Pierard, L. A., Davis, C. E., Koller, M. T., Bucher, H. C., Steyerberg, E. W., Ridker, P. M, Glynn, R. J. (2009). Rosuvastatin in Patients with Elevated C-Reactive Protein. NEJM 360: 1038-1042 [Full Text]  
• Hong, Y. J., Jeong, M. H., Choi, Y. H., Ko, J. S., Lee, M. G., Kang, W. Y., Lee, S. E., Kim, S. H., Park, K. H., Sim, D. S., Yoon, N. S., Yoon, H. J., Kim, K. H., Park, H. W., Kim, J. H., Ahn, Y., Cho, J. G., Park, J. C., Kang, J. C. (2009). Plaque characteristics in culprit lesions and inflammatory status in diabetic acute coronary syndrome patients.. J Am Coll Cardiol Img 2: 339-349 [Abstract] [Full Text]  
• Wedel, H., McMurray, J. J.V., Lindberg, M., Wikstrand, J., Cleland, J. G.F., Cornel, J. H., Dunselman, P., Hjalmarson, A., Kjekshus, J., Komajda, M., Kuusi, T., Vanhaecke, J., Waagstein, F., on behalf of the CORONA Study Group, (2009). Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 11: 281-291 [Abstract] [Full Text]  
• Ray, K. K., Cannon, C. P., Cairns, R., Morrow, D. A., Ridker, P. M, Braunwald, E. (2009). Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes: Results From PROVE IT-TIMI 22. Arterioscler. Thromb. Vasc. Bio. 29: 424-430 [Abstract] [Full Text]  
• Montecucco, F., Burger, F., Pelli, G., Poku, N. K., Berlier, C., Steffens, S., Mach, F. (2009). Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology (Oxford) 48: 233-242 [Abstract] [Full Text]  
• Paraskevas, K. I., Bessias, N., Papas, T. T., Andrikopoulos, V., Mikhailidis, D. P. (2009). Is High-sensitivity C-reactive Protein Associated With Subclinical Peripheral Atherosclerosis?. ANGIOLOGY 60: 8-11  
• Ridker, P. M (2009). Myocardial Infarction in a 72-Year-Old Woman with Low LDL-C and Increased hsCRP: Implications for Statin Therapy. Clin. Chem. 55: 369-374 [Full Text]  
• Devaraj, S., Yun, J.-M., Duncan-Staley, C., Jialal, I. (2009). C-reactive protein induces M-CSF release and macrophage proliferation. J. Leukoc. Biol. 85: 262-267 [Abstract] [Full Text]  
• Singh, U., Devaraj, S., Jialal, I. (2009). C-Reactive Protein Stimulates Myeloperoxidase Release from Polymorphonuclear Cells and Monocytes: Implications for Acute Coronary Syndromes. Clin. Chem. 55: 361-364 [Abstract] [Full Text]  
• Scirica, B. M., Cannon, C. P., Sabatine, M. S., Jarolim, P., Sloane, S., Rifai, N., Braunwald, E., Morrow, D. A., for the PROVE IT-TIMI 22 Investigators, (2009). Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death. Clin. Chem. 55: 265-273 [Abstract] [Full Text]  
• Shen, J., Ordovas, J. M. (2009). Impact of Genetic and Environmental Factors on hsCRP Concentrations and Response to Therapeutic Agents. Clin. Chem. 55: 256-264 [Abstract] [Full Text]  
• Mora, S., Musunuru, K., Blumenthal, R. S. (2009). The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines. Clin. Chem. 55: 219-228 [Abstract] [Full Text]  
• Ridker, P. M (2009). C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease. Clin. Chem. 55: 209-215 [Full Text]  
• Hingorani, A. D., Shah, T., Casas, J. P., Humphries, S. E., Talmud, P. J. (2009). C-Reactive Protein and Coronary Heart Disease: Predictive Test or Therapeutic Target?. Clin. Chem. 55: 239-255 [Abstract] [Full Text]  
• Schumacher, W., Cockcroft, J., Timpson, N. J., McEniery, C. M., Gallacher, J., Rumley, A., Lowe, G., Smith, G. D., Wilkinson, I. B., Ben-Shlomo, Y. (2009). Association Between C-Reactive Protein Genotype, Circulating Levels, and Aortic Pulse Wave Velocity. Hypertension 53: 150-157 [Abstract] [Full Text]  
• Ganz, P., Hsue, P. Y. (2009). Individualized approach to the management of coronary heart disease identifying the nonresponders before it is too late.. J Am Coll Cardiol 53: 331-333 [Full Text]  
• Liu, P.-Y., Liu, Y.-W., Lin, L.-J., Chen, J.-H., Liao, J. K. (2009). Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation. Circulation 119: 131-138 [Abstract] [Full Text]  
• Grammer, T. B., Marz, W., Renner, W., Bohm, B. O., Hoffmann, M. M. (2009). C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LURIC study. Eur Heart J 30: 170-182 [Abstract] [Full Text]  
• SHISHEHBOR, M. H., HAZEN, S. L. (2009). JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?. Cleveland Clinic Journal of Medicine 76: 37-44 [Abstract] [Full Text]  
• Hamm, C. W., Möllmann, H., Bassand, J.-P., van de Werf, F. (2009). CHAPTER 16 Acute Coronary Syndromes. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Ammirati, E., Vermi, A.-C., Cianflone, D., Banfi, M., Foglieni, C., Godino, C., Airoldi, F., Ferri, L. A., Gorman, C. L., Manfredi, A. A., Maseri, A., Cope, A. P., Monaco, C. (2008). Expansion of T-Cell Receptor {zeta}dim Effector T Cells in Acute Coronary Syndromes. Arterioscler. Thromb. Vasc. Bio. 28: 2305-2311 [Abstract] [Full Text]  
• Ridker, P. M, Danielson, E., Fonseca, F. A.H., Genest, J., Gotto, A. M. Jr., Kastelein, J. J.P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., Nordestgaard, B. G., Shepherd, J., Willerson, J. T., Glynn, R. J., the JUPITER Study Group, (2008). Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. NEJM 359: 2195-2207 [Abstract] [Full Text]  
• Isma, N., Barani, J., Mattiasson, I., Lindblad, B., Gottsater, A. (2008). Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia. ANGIOLOGY 59: 542-548 [Abstract]  
• Bakhai, A. (2008). Adipokines--targeting a root cause of cardiometabolic risk. QJM 101: 767-776 [Abstract] [Full Text]  
• Edwards, A. V. G., White, M. Y., Cordwell, S. J. (2008). The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery. Mol. Cell. Proteomics 7: 1824-1837 [Abstract] [Full Text]  
• Adam, O., Neuberger, H.-R., Bohm, M., Laufs, U. (2008). Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors. Circulation 118: 1285-1293 [Full Text]  
• Bankier, B., Barajas, J., Martinez-Rumayor, A., Januzzi, J. L. (2008). Association between C-reactive protein and generalized anxiety disorder in stable coronary heart disease patients. Eur Heart J 29: 2212-2217 [Abstract] [Full Text]  
• FELDMAN, L. S., BROTMAN, D. J. (2008). Perioperative statins: More than lipid-lowering?. Cleveland Clinic Journal of Medicine 75: 654-662 [Abstract] [Full Text]  
• Bonaca, M. P., Morrow, D. A. (2008). Defining a Role for Novel Biomarkers in Acute Coronary Syndromes. Clin. Chem. 54: 1424-1431 [Abstract] [Full Text]  
• Jaffe, A. S. (2008). Key Issues in the Developing Synergism between Cardiovascular Imaging and Biomarkers. Clin. Chem. 54: 1432-1442 [Abstract] [Full Text]  
• Wee, C. C., Girotra, S., Weinstein, A. R., Mittleman, M. A., Mukamal, K. J. (2008). The Relationship Between Obesity and Atherosclerotic Progression and Prognosis Among Patients With Coronary Artery Bypass Grafts: The Effect of Aggressive Statin Therapy. J Am Coll Cardiol 52: 620-625 [Abstract] [Full Text]  
• Arslan, F., Pasterkamp, G., de Kleijn, D. P. (2008). Unraveling Pleiotropic Effects Of Statins: Bit By Bit, a Slow Case With Perspective. Circ. Res. 103: 334-336 [Full Text]  
• Samson, R. H. (2008). The Role of Statin Drugs in the Management of the Peripheral Vascular Patient. VASC ENDOVASCULAR SURG 42: 352-366 [Abstract]  
• Arain, F. A., Cooper, L. T. Jr (2008). Peripheral Arterial Disease: Diagnosis and Management. Mayo Clin Proc. 83: 944-950 [Abstract] [Full Text]  
• Ridker, P. M (2008). The Time for Cardiovascular Inflammation Reduction Trials Has Arrived: How Low to Go for hsCRP?. Arterioscler. Thromb. Vasc. Bio. 28: 1222-1224 [Full Text]  
• Arima, H., Kubo, M., Yonemoto, K., Doi, Y., Ninomiya, T., Tanizaki, Y., Hata, J., Matsumura, K., Iida, M., Kiyohara, Y. (2008). High-Sensitivity C-Reactive Protein and Coronary Heart Disease in a General Population of Japanese: The Hisayama Study. Arterioscler. Thromb. Vasc. Bio. 28: 1385-1391 [Abstract] [Full Text]  
• Bhavnani, S. P., Coleman, C. I., White, C. M., Clyne, C. A., Yarlagadda, R., Guertin, D., Kluger, J. (2008). Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy. Europace 10: 854-859 [Abstract] [Full Text]  
• Yasue, H., Mizuno, Y., Harada, E., Itoh, T., Nakagawa, H., Nakayama, M., Ogawa, H., Tayama, S., Honda, T., Hokimoto, S., Ohshima, S., Hokamura, Y., Kugiyama, K., Horie, M., Yoshimura, M., Harada, M., Uemura, S., Saito, Y., for the SCAST (Statin and Coronary Artery Spasm Tr, (2008). Effects of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Fluvastatin, on Coronary Spasm After Withdrawal of Calcium-Channel Blockers. J Am Coll Cardiol 51: 1742-1748 [Abstract] [Full Text]  
• Kolz, M., Koenig, W., Muller, M., Andreani, M., Greven, S., Illig, T., Khuseyinova, N., Panagiotakos, D., Pershagen, G., Salomaa, V., Sunyer, J., Peters, A., for the AIRGENE Study Group, (2008). DNA variants, plasma levels and variability of C-reactive protein in myocardial infarction survivors: results from the AIRGENE study. Eur Heart J 29: 1250-1258 [Abstract] [Full Text]  
• Lund, S. S, Tarnow, L., Stehouwer, C. D A, Schalkwijk, C. G, Teerlink, T., Gram, J., Winther, K., Frandsen, M., Smidt, U. M, Pedersen, O., Parving, H.-H., Vaag, A. A (2008). Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 158: 631-641 [Abstract] [Full Text]  
• Shen, J., Arnett, D. K., Parnell, L. D., Peacock, J. M., Lai, C.-Q., Hixson, J. E., Tsai, M. Y., Province, M. A., Straka, R. J., Ordovas, J. M. (2008). Association of Common C-Reactive Protein (CRP) Gene Polymorphisms With Baseline Plasma CRP Levels and Fenofibrate Response: The GOLDN Study. Diabetes Care 31: 910-915 [Abstract] [Full Text]  
• Mohler, E. R. III, Ballantyne, C. M., Davidson, M. H., Hanefeld, M., Ruilope, L. M., Johnson, J. L., Zalewski, A., for the Darapladib Investigators, (2008). The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Am Coll Cardiol 51: 1632-1641 [Abstract] [Full Text]  
• Danese, A., Moffitt, T. E., Pariante, C. M., Ambler, A., Poulton, R., Caspi, A. (2008). Elevated Inflammation Levels in Depressed Adults With a History of Childhood Maltreatment. Arch Gen Psychiatry 65: 409-415 [Abstract] [Full Text]  
• Weintraub, W. S., Diamond, G. A. (2008). Predicting Cardiovascular Events with Coronary Calcium Scoring. NEJM 358: 1394-1396 [Full Text]  
• Shirali, A. C., Bia, M. J. (2008). Management of Cardiovascular Disease in Renal Transplant Recipients. CJASN 3: 491-504 [Abstract] [Full Text]  
• Murphy, D. M., Forrest, I. A., Corris, P. A., Johnson, G. E., Small, T., Jones, D., Fisher, A. J., Egan, J. J., Cawston, T. E., Ward, C., Lordan, J. L. (2008). Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L592-L599 [Abstract] [Full Text]  
• Nesto, R. W., Mackie, K. (2008). Endocannabinoid system and its implications for obesity and cardiometabolic risk. Eur Heart J Suppl 10: B34-B41 [Abstract] [Full Text]  
• Gill, J. S. (2008). Cardiovascular Disease in Transplant Recipients: Current and Future Treatment Strategies. CJASN 3: S29-S37 [Abstract] [Full Text]  
• Miller, M., Cannon, C. P., Murphy, S. A., Qin, J., Ray, K. K., Braunwald, E., for the PROVE IT-TIMI 22 Investigators, (2008). Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial.. J Am Coll Cardiol 51: 724-730 [Abstract] [Full Text]  
• Lee, S-S., Singh, S., Magder, L., Petri, M. (2008). Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. Lupus 17: 114-123 [Abstract]  
• Berbee, J. F. P., Mooijaart, S. P., de Craen, A. J. M., Havekes, L. M., van Heemst, D., Rensen, P. C. N., Westendorp, R. G. J. (2008). Plasma Apolipoprotein CI Protects Against Mortality From Infection in Old Age. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 63: 122-126 [Abstract] [Full Text]  
• Ridker, P. M (2008). High-Sensitivity C-Reactive Protein as a Predictor of All-Cause Mortality: Implications for Research and Patient Care. Clin. Chem. 54: 234-237 [Full Text]  
• Bedard, P. W., Clerin, V., Sushkova, N., Tchernychev, B., Antrilli, T., Resmini, C., Keith, J. C. Jr., Hennan, J. K., Kaila, N., DeBernardo, S., Janz, K., Wang, Q., Crandall, D. L., Schaub, R. G., Shaw, G. D., Carter, L. L. (2008). Characterization of the Novel P-Selectin Inhibitor PSI-697 [2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] Quinoline-4-carboxylic acid] in Vitro and in Rodent Models of Vascular Inflammation and Thrombosis. J. Pharmacol. Exp. Ther. 324: 497-506 [Abstract] [Full Text]  
• Iakoubova, O. A., Sabatine, M. S., Rowland, C. M., Tong, C. H., Catanese, J. J., Ranade, K., Simonsen, K. L., Kirchgessner, T. G., Cannon, C. P., Devlin, J. J., Braunwald, E. (2008). Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.. J Am Coll Cardiol 51: 449-455 [Abstract] [Full Text]  
• Kircher, M. F., Grimm, J., Swirski, F. K., Libby, P., Gerszten, R. E., Allport, J. R., Weissleder, R. (2008). Noninvasive In Vivo Imaging of Monocyte Trafficking to Atherosclerotic Lesions. Circulation 117: 388-395 [Abstract] [Full Text]  
• Packard, R. R. S., Libby, P. (2008). Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction. Clin. Chem. 54: 24-38 [Abstract] [Full Text]  
• Williams, E. S., Shah, S. J., Ali, S., Na, B. Y., Schiller, N. B., Whooley, M. A. (2008). C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. Eur J Heart Fail 10: 63-69 [Abstract] [Full Text]  
• Ardigo, D., Assimes, T. L., Fortmann, S. P., Go, A. S., Hlatky, M., Hytopoulos, E., Iribarren, C., Tsao, P. S., Tabibiazar, R., Quertermous, T., for the ADVANCE Investigators, (2007). Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. Physiol. Genomics 31: 402-409 [Abstract] [Full Text]  
• Szwast, S. J., Hendrie, H. C., Lane, K. A., Gao, S., Taylor, S. E., Unverzagt, F., Murrell, J., Deeg, M., Ogunniyi, A., Farlow, M. R., Hall, K. S. (2007). Association of statin use with cognitive decline in elderly African Americans. Neurology 69: 1873-1880 [Abstract] [Full Text]  
• Devaraj, S., Tang, R., Adams-Huet, B., Harris, A., Seenivasan, T., de Lemos, J. A, Jialal, I. (2007). Effect of high-dose {alpha}-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am. J. Clin. Nutr. 86: 1392-1398 [Abstract] [Full Text]  
• Nylaende, M., Kroese, A.J., Morken, B., Stranden, E., Sandbaek, G., Lindahl, A.K., Arnesen, H., Seljeflot, I. (2007). Beneficial effects of 1-year optimal medical treatment with and without additional PTA on inflammatory markers of atherosclerosis in patients with PAD. Results from the Oslo Balloon Angioplasty versus Conservative Treatment (OBACT) study. Vasc Med 12: 275-283 [Abstract]  
• Gortney, J. S., Sanders, R. M. (2007). Impact of C-reactive protein on treatment of patients with cardiovascular disease. Am J Health Syst Pharm 64: 2009-2016 [Abstract] [Full Text]  
• Okura, H., Taguchi, H., Kubo, T., Toda, I., Yoshiyama, M., Yoshikawa, J., Yoshida, K. (2007). Impact of arterial remodelling and plaque rupture on target and non-target lesion revascularisation after stent implantation in patients with acute coronary syndrome: an intravascular ultrasound study. Heart 93: 1219-1225 [Abstract] [Full Text]  
• Memoli, B., Procino, A., Calabro, P., Esposito, P., Grandaliano, G., Pertosa, G., Prete, M. D., Andreucci, M., Lillo, S. D., Ferulano, G., Cillo, C., Savastano, S., Colao, A., Guida, B. (2007). Inflammation may modulate IL-6 and C-reactive protein gene expression in the adipose tissue: the role of IL-6 cell membrane receptor. Am. J. Physiol. Endocrinol. Metab. 293: E1030-E1035 [Abstract] [Full Text]  
• Scirica, B. M., Morrow, D. A., Cannon, C. P., de Lemos, J. A., Murphy, S., Sabatine, M. S., Wiviott, S. D., Rifai, N., McCabe, C. H., Braunwald, E., for the Thrombolysis in Myocardial Infarction (TIM, (2007). Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes. Clin. Chem. 53: 1800-1807 [Abstract] [Full Text]  
• Decensi, A., Gandini, S., Serrano, D., Cazzaniga, M., Pizzamiglio, M., Maffini, F., Pelosi, G., Daldoss, C., Omodei, U., Johansson, H., Macis, D., Lazzeroni, M., Penotti, M., Sironi, L., Moroni, S., Bianco, V., Rondanina, G., Gjerde, J., Guerrieri-Gonzaga, A., Bonanni, B. (2007). Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users. JCO 25: 4201-4209 [Abstract] [Full Text]  
• Martin-Fuentes, P., Civeira, F., Recalde, D., Garcia-Otin, A. L., Jarauta, E., Marzo, I., Cenarro, A. (2007). Individual Variation of Scavenger Receptor Expression in Human Macrophages with Oxidized Low-Density Lipoprotein Is Associated with a Differential Inflammatory Response. J. Immunol. 179: 3242-3248 [Abstract] [Full Text]  
• Kalantar-Zadeh, K. (2007). Inflammatory Marker Mania in Chronic Kidney Disease: Pentraxins at the Crossroad of Universal Soldiers of Inflammation. CJASN 2: 872-875 [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157 [Full Text]  
• Momin, A., Melikian, N., Wheatcroft, S. B., Grieve, D., John, L. C., El Gamel, A., Marrinan, M. T., Desai, J. B., Driver, C., Sherwood, R., Shah, A. M., Kearney, M. T. (2007). The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 134: 335-341 [Abstract] [Full Text]  
• Jialal, I., Miguelino, E., Griffen, S. C., Devaraj, S. (2007). Concomitant Reduction of Low-Density Lipoprotein-Cholesterol and Biomarkers of Inflammation with Low-Dose Simvastatin Therapy in Patients with Type 1 Diabetes. J. Clin. Endocrinol. Metab. 92: 3136-3140 [Abstract] [Full Text]  
• Afilalo, J., Majdan, A. A, Eisenberg, M. J (2007). Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 93: 914-921 [Abstract] [Full Text]